Bristol-Myers Squibb Company’s recently made public that its Board Chair and CEO Caforio Giovanni unloaded Company’s shares for reported $17.92 million on Feb 06. In the deal valued at $74.65 per share,240,000 shares were sold. As a result of this transaction, Caforio Giovanni now holds 236,104 shares worth roughly $ 16.36 million.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Then, Powell Ann sold 11,183 shares, generating $835,258 in total proceeds. Upon selling the shares at $74.69, the EVP, Chief Human Resources now owns 23,043 shares.
Before that, Powell Ann sold 16,250 shares. Bristol-Myers Squibb Company shares valued at $1,307,312 were divested by the EVP, Chief Human Resources at a price of $80.45 per share. As a result of the transaction, Powell Ann now holds 34,226 shares, worth roughly $2.37 million.
Cantor Fitzgerald initiated its Bristol-Myers Squibb Company [BMY] rating to an Overweight in a research note published on Friday, January 17, 2023; the price target was $95. PT values the company’s stock at a premium of 27.05 to its Friday closing price. A number of analysts have revised their coverage, including Credit Suisse’s analysts, who began to cover the stock in mid November with a ‘”a Neutral”‘ rating. Guggenheim also remained covering BMY and has decreased its forecast on October 10, 2022 with a “Neutral” recommendation from previously “Buy” rating. Berenberg revised its rating on September 14, 2022. It rated BMY as “a Hold” which previously was an “a Buy”.
Price Performance Review of BMY
On Friday, Bristol-Myers Squibb Company [NYSE:BMY] saw its stock jump 0.16% to $69.30. On the same session, the stock had its day’s lowest price of $68.81, but rose to a high of $69.42. Over the last five days, the stock has lost -1.25%. Bristol-Myers Squibb Company shares have fallen nearly -3.68% since the year began. Nevertheless, the stocks have risen 0.65% over the past one year. While a 52-week high of $81.43 was reached on 02/06/23, a 52-week low of $65.95 was recorded on 03/01/23. SMA at 50 days reached $72.11, while 200 days put it at $73.89. A total of 6.54 million shares were traded, compared to the trading of 6.07 million shares in the previous session.
Levels Of Support And Resistance For BMY Stock
The 24-hour chart illustrates a support level at 68.93, which if violated will result in even more drops to 68.57. On the upside, there is a resistance level at 69.54. A further resistance level may holdings at 69.79. The Relative Strength Index (RSI) on the 14-day chart is 36.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.41, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.81%. Stochastics %K at 13.49% indicates the stock is a buying.
How much short interest is there in Bristol-Myers Squibb Company?
A steep rise in short interest was recorded in Bristol-Myers Squibb Company stocks on Jan 12, 2023, dropping by -3.92 million shares to a total of 20.96 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2022 was 24.88 million shares. There was a decline of -18.7%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 0.99% of the overall stock float, the days-to-cover ratio (short ratio) fell to 2.29.
Bristol-Myers Squibb Company [BMY] – Who Are The Largest Shareholders?
In filings from The Vanguard Group, Inc., it is revealed that the company now owns 193,861,505 shares, or roughly 9.12% of the outstanding BMY shares. In other words, the investor’s shares have risen by 2,894,409 from its previous 13-F filing of 190967096.0. Additionally, BlackRock Fund Advisors increased 2.56% of its stake after which the total value it holdings stand at $8,227,436,251, while SSgA Funds Management, Inc. added 0.46% of its stake to hold $6.74 billion in the firm. Over the last quarter, JPMorgan Investment Management, I sold -530,845 shares of Bristol-Myers Squibb Company, while Capital Research & Management Co sold 320,605 shares. At present, Fidelity Management & Research Co is holding 40,394,424 shares valued at $2.93 billion. Geode Capital Management LLC owned 38,724,114 shares of the company at the time of its most recent 13F filing, worth $2.81 billion.
According to FactSet, Bristol-Myers Squibb Company’s share price will average $81.53 in the next year, based on opinions of analysts polled by the firm. This is up nearly 18.51 percent from its previous closing price of $69.19. Analysts expect Bristol-Myers Squibb Company stock to reach the higher price of $95.00, while the lowest price estimate is $62.00. However, 20 analysts have rated BMY stock as an Overweight in their predictions for 2023.